Navigation Links
Keith Denner Extends Current Technology's Chairman and CEO Options
Date:4/10/2008

VANCOUVER, British Columbia, April 10 /PRNewswire-FirstCall/ -- On July 6, 2006, Current Technology Corporation (the "Company") announced that Keith Denner had granted to the Chairman and to the Chief Executive Officer, for nominal consideration, options ("Options") to purchase common shares in the capital of the Company, from his personal holdings, under the following terms and conditions:

i) total number of shares under option -- 3,000,000;

ii) exercise price -- $0.38 (all funds USD) per share;

iii) vesting -- fifty percent of the options to vest if the Company's

shares close at $0.78 or higher, and the remaining fifty percent to

vest if they close at $1.14 or higher;

iv) term -- the option to expire on July 5, 2008;

v) Mr. Denner to have the right to donate all or a portion of the

3,000,000 shares to a charity or charities, subject to the terms of

the option agreements; and

vi) Robert Kramer must be an officer of the Company at the time of

exercise of the option.

The Company's Board of Directors has reviewed the terms of the options and confirmed they are fair to the Company and that no consideration was provided by the Company to Mr. Denner to induce him to grant the options.

"I have been and remain a long-term supporter of the Company," stated Mr. Denner. "I believe it is in the shareholders' best interests to incentivize the Chairman and CEO of the Company and I am pleased to do my part by offering a portion of my personal holdings to that end. I am very supportive of the Company's recent acquisition of a controlling interest in Celevoke, Inc. and feel it appropriate to extend the term of my option to Mr. Kramer for another year to July 5, 2009."

Mr. Denner owns 16,619,266 common shares (representing approximately 12.83% of the issued and outstanding shares of the Company) and warrants to purchase an additional 27,548
'/>"/>

SOURCE Current Technology Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Atlanta Falcons Linebacker Keith Brooking Prepares to Run for Something Better at ING Georgia Marathon
2. Therap Services Welcomes Anna Keith to the US Customer Support Team
3. Viant Appoints Keith Vangeison as Executive Vice President of Network Development
4. Verus Pharmaceuticals Announces Promotion of Robert W. Keith to Chief Executive Officer
5. Keith Taft Named General Manager of UltraTape Industries
6. Parker Extends Precise Medical Seal Capability; Acquires Hi-Tech Group Companies
7. The Quantum Group Extends CEOs Employment Agreement
8. Hands on Disaster Response Extends Cyclone Relief Project
9. PROGNOSIS Extends its Popular IP Telephony Management Software to Support Nortel Environments
10. FDA Extends Review Timeline for Additional Indication for Antibiotic DORIBAX(TM)
11. Actavis Extends Portfolio With Four New Products in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 2Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 3Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 4Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 2Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 3Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 4Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 5Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 6Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 7Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 8